Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

INOVIQ - Healthcare Conference Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ - Appendix 4C & Quarterly Activities Report-September 2022 (ASX:IIQ)

SubB2M-based Surface Plasmon Resonance (SPR) test to be developed with Nicoya on the Alto™ Digital SPR instrument Contract sales force appointed via agreement with P...read more

INOVIQ - Canadian Patent Granted for BARD1 Technology (ASX:IIQ)

Key points: -- Canadian Patent No. 2,929,457 granted covering lung cancer diagnosis -- IP protection in Canada for BARD1 autoantibody test for diagnosis of lung cancer in Canada Melbourne, Au...read more

INOVIQ - Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ - Notice of Annual General Meeting (ASX:IIQ)

Melbourne, Australia, 27 October 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) advises that INOVIQ’s 2022 Annual General Meeting (AGM) is to be held at the offices of Grant Thornton, ...read more

INOVIQ - Receipt of R&D Tax Incentive Refund (ASX:IIQ)

INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) is pleased to advise that the Company has received $865,625 from the federal government’s Research and Development (R&D) Tax Ince...read more

INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform (ASX:IIQ)

Highlights: Contract Research Agreement signed with Nicoya to transfer, develop and evaluate a SubB2M-based Surface Plasmon Resonance (SPR) test on the Alto™ Digital ...read more

INOVIQ - 2022 Annual Report and update on results (ASX:IIQ)

INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) is pleased to release its Annual Report for the 2022 financial year. The Company reported a total comprehensive loss for the year of $6.260m in th...read more

INOVIQ - Appendix 4E and Preliminary Financial Report (ASX:IIQ)

To view the Appendix and Preliminary Financial Report, download the attached PDF.

INOVIQ Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ - Appendix 4C & Quarterly Activities Report - June 2022 (ASX:IIQ)

INOVIQ Limited (ASX:IIQ) today released its Appendix 4C and Quarterly Business Update for the quarter ended 30 June 2022. For more information, download the attached PDF.

INOVIQ - Positive SubB2M IHC Results for Melanoma (ASX:IIQ)

-- Immunohistochemistry (IHC) feasibility study successfully completed using INOVIQ’s SubB2M probe to aid in diagnosis of malignant melanoma in tis...read more

INOVIQ - hTERT US Patent Granted (ASX:IIQ)

Highlights -- US Patent No 11,391,738 granted covering the hTERT technology -- Provides further IP protection for hTERT in the USA for cancer applications beyond bladder cancer Melbourne,&nbs...read more

INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out (ASX:IIQ)

-- INOVIQ engages US-based Percorso Life Sciences to provide contract sales force and logistics services to accelerate commercial roll-out of EXO-NET® products in the USA -- Contract sales forc...read more

INOVIQ - SubB2M US Patent Grant and Program Update (ASX:IIQ)

Melbourne, Australia, 1 July 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) announces that United States of America Patent No 11,371,033 entitled ‘Subtilase cytotoxin B subunit mutant&...read more

Viewing: 31 - 45 of 100 Previous | Next